


Prostate Cancer Awareness Month March 2022



2nd

Most common
cancer death
in men



1/8

Men likely to be
diagnosed with
prostate cancer in
their lifetime

Top NEWS item: Multi-marker prostate cancer screening achieves higher detection rate¹

Screening for prostate specific antigen (PSA) and human kallikrein-related peptidase 2 (hK2) increases accuracy of diagnosis. Reducing overdiagnosis and overtreatment of patients due to false positives.

90%

Detection rate when men with 'greater risk' are screened 5 yearly²

"The approach is **innovative for cancer**, as it screens people on the basis of their overall risk rather than the results of a single test"²

ASCO-GU 2022 highlighted positive outcomes for patients from trials



Metastatic castration-resistant prostate cancer (mCRPC)

34% reduction in disease progression

when patients were treated first-line with Lynparza (olaparib) + abiraterone. It is now set to be the PARPi of choice after the promising data.³

Metastatic hormone-sensitive prostate cancer (mHSPC)

27% reduction in disease progression

for all patients with damaged DNA-repair genes when patients have niraparib added to their abiraterone acetate/prednisone treatment. Reduction in disease progression increased to 47% when patients had BRCA 1/2 alterations.^{4,5}

32% reduction in risk of death with novel triplet therapy compared with SoC. The combination of androgen deprivation therapy + docetaxel + darolutamide showed positive results for patients, including no increase in side effects.^{4,6}

Quick Facts

7

Ongoing Phase IV trials in the UK

- 3 trials investigating radium dichloride (Xofigo) and sponsored by Bayer
- The other 4 trials were sponsored by Kings College London, University College London, Guys and St. Thomas NHS Foundation Trust and Recordati SpA
- 6 trials have efficacy endpoints
- 5 trials have safety endpoints
- 2 have pharmacodynamics endpoints
- 1 have quality of life endpoints

1. <https://journals.sagepub.com/doi/10.1177/09691413221076415>

2. <https://www.medscape.com/viewarticle/969838>
<https://www.astrazeneca.com/media-centre/press-releases/2022/>

3. <https://www.pcf.org/blog/highlights-of-asco-gu-2022-part-1/>

4. <https://www.urotoday.com/conference-highlights/asco-gu-2022/>

5. <https://media.bayer.com/>

6.

